<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04792398</url>
  </required_header>
  <id_info>
    <org_study_id>BRUX-XIT</org_study_id>
    <nct_id>NCT04792398</nct_id>
  </id_info>
  <brief_title>Bruxism Xeomin® Intervention Trial</brief_title>
  <acronym>BRUX-XIT</acronym>
  <official_title>Effects of Botulinum Toxin Type A (Xeomin®) Injections Into Bilateral Masseter Muscles for Management of Bruxism and Associated Symptoms: Single Center Open Label Longitudinal Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dominik Ettlin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merz Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether severe masticatory muscle spasms during sleep&#xD;
      (e.g. teeth clenching and grinding, known as &quot;bruxism&quot; in technical jargon) demonstrably&#xD;
      decrease after application of botulinum toxin type A (Xeomin®). Xeomin® has so far been used&#xD;
      to relieve spasms of other muscles and is an approved drug in Switzerland. This study is now&#xD;
      intended to test the suitability of this drug for relaxation of the masseter muscle.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bruxism is a prevalent condition that differentially burdens individuals. The overall&#xD;
      objective of this pilot study is to measure the effects of BTX-A (Xeomin®) injections into&#xD;
      bilateral masseter muscles for the management of sleep bruxism and associated symptoms. The&#xD;
      hypothesis is that BTX-A reduces masticatory muscle activity. The aim of this study is to&#xD;
      instrumentally monitor subjects closely over an extended time period of three months before&#xD;
      and after application of BTX-A.&#xD;
&#xD;
      Botulinum toxin type A ( BTX A; Xeomin ® ) temporarily blocks neuromuscular synapses. It is&#xD;
      successfully and safely used therapeutically in various types of movement disorders and in&#xD;
      chronic migraineurs. The mechanism of action of this treatment is related to a reduction of&#xD;
      neurotransmitter release leading to reduced muscle activity.&#xD;
&#xD;
      The following Null hypothesis will be tested:&#xD;
&#xD;
      Injections of Xeomin® into the masseter muscles bilaterally (25 Units per muscle applied with&#xD;
      2 injections in each muscle) have no effect on bruxism measured by A) Masticatory muscle&#xD;
      activity (1° objective) B) Subjects' well-being (2° objective) C) Sensitivity of masticatory&#xD;
      muscles and jaw joints (2° objective) D) Anxiety over tooth wear (2° objective) E) Disturbed&#xD;
      sleep by bed partner (2° objective)&#xD;
&#xD;
      Following instruments will be used:&#xD;
&#xD;
        1. WISE questionnaires. A comprehensive web-based interdisciplinary symptom evaluation&#xD;
           tool.&#xD;
&#xD;
        2. Algometer for sensitivity measure of masticatory muscles and jaw joints.&#xD;
&#xD;
        3. Bio-signal recorder. Parallel to the Electromyography (EMG) of the masseter muscles,&#xD;
           other bio-signals such as a number of electroencephalographic (EEG) derivations,&#xD;
           electrooculogram (EOG ) as well as an electrocardiogram (ECG) will be recorded, in order&#xD;
           to detect sleep stages and better identify bruxism episodes. The device used in this&#xD;
           study has been approved for projects NIH #2R01DE016417-05A1 and #1 R01DE028548-01.&#xD;
&#xD;
        4. Ultrasound for masseter muscle thickness measure&#xD;
&#xD;
        5. Dual-color chewing gum for chewing efficiency measure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Observational study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of maximum EMG amplitudes</measure>
    <time_frame>days 1-14, days 29-42</time_frame>
    <description>Change of average of maximum EMG amplitudes of all bruxism events per night between days 1-14 (baseline) and days 29-42.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Verbal Rating Scale of Global impression of change</measure>
    <time_frame>day 154</time_frame>
    <description>Verbal Rating Scale (VRS) containing the following levels &quot;much worse&quot;, &quot;slightly worse&quot;, &quot;no change&quot;, &quot;slightly improved&quot;, &quot;much improved&quot; of &quot;global impression of change&quot; at the end of the study (day 154)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of maximum EMG amplitude</measure>
    <time_frame>days 1-14, days 15-28, days 85-98, days 141-154</time_frame>
    <description>Change of average of maximum EMG amplitudes of all bruxism events per night between days 1-14 (baseline) and days 15-28, 85-98, and 141-154.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EMG amplitude at maximum voluntary contraction</measure>
    <time_frame>days 1-14, days 15-28, days 85-98, days 141-154</time_frame>
    <description>EMG signal amplitude (RMS) at maximum voluntary contraction (MVC) in [V]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of masseter contraction episodes per hour (N/h)</measure>
    <time_frame>days 1-14, days 15-28, days 85-98, days 141-154</time_frame>
    <description>number of masseter contraction episodes per hour calculated from EMG signal amplitude normalized on MVC [N/h]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of masseter contraction episodes (Dur)</measure>
    <time_frame>days 1-14, days 15-28, days 85-98, days 141-154</time_frame>
    <description>duration of masseter contraction episodes in [sec] calculated from EMG signal amplitude normalized on MVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EMG-Index</measure>
    <time_frame>days 1-14, days 15-28, days 85-98, days 141-154</time_frame>
    <description>EMG-Index = 0.5 x N/h + Dur</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EMG Duty Factor</measure>
    <time_frame>days 1-14, days 15-28, days 85-98, days 141-154</time_frame>
    <description>EMG duty factor = % duration of muscle activity/total recording time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of masticatory muscles and jaw joints</measure>
    <time_frame>day 1, 14, 28, 42, 98, 154</time_frame>
    <description>Sensitivity of masticatory muscles and jaw joints in [N]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-report of bruxism</measure>
    <time_frame>day 1, 14, 28, 42, 98, 154</time_frame>
    <description>Yes/No answer to direct question</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numerical Rating Scale masseter muscle pain</measure>
    <time_frame>day 1, 14, 28, 42, 98, 154</time_frame>
    <description>Numerical Rating Scale (NRS) (0-10) with 0 = no pain and 10 = worst imaginable pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numerical Rating Scale report of spontaneous facial pain</measure>
    <time_frame>day 1, 14, 28, 42, 98, 154</time_frame>
    <description>Numerical Rating Scale (NRS) (0-10) with 0 = no pain and 10 = worst imaginable pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numerical Rating Scale report of jaw movement related facial pain</measure>
    <time_frame>day 1, 14, 28, 42, 98, 154</time_frame>
    <description>Numerical Rating Scale (NRS) (0- 10) with 0 = no pain and 10 = worst imaginable pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numerical Rating Scale report of anxiety over tooth wear</measure>
    <time_frame>day 1, 14, 28, 42, 98, 154</time_frame>
    <description>Numerical Rating Scale (NRS) (0-10) with 0 = no anxiety and 10 = worst imaginable anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numerical Rating Scale disturbed sleep of bed partner</measure>
    <time_frame>day 1, 14, 28, 42, 98, 154</time_frame>
    <description>Numerical Rating Scale (NRS) (0-10) with 0 = no disturbed sleep and 10 = worst imaginable sleep</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Sleep Bruxism, Adult</condition>
  <arm_group>
    <arm_group_label>Sleep Bruxism Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ultrasound guided BTX-A injection: 25 units (divided in two injections) in each masseter muscle.&#xD;
One-time intervention. Effect observation by measuring various biosignals (EMG, EOG, EEG), bite force, chewing efficiency, psychometric assessments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Incobotulinumtoxin A (BTX A) Xeomin®</intervention_name>
    <description>Injections into the masseter muscles bilaterally (25 Units per muscle applied with 2 injections in each muscle)</description>
    <arm_group_label>Sleep Bruxism Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-90 years;&#xD;
&#xD;
          -  patients complaining of bruxism and/or bruxism-related symptoms.&#xD;
&#xD;
          -  Sufficient knowledge of German to understand the patient information and the trial&#xD;
             arrangement.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications for Xeomin® treatment such as generalized disorders of muscle&#xD;
             activity (myasthenia gravis, Lambert-Eaton-Rooke syndrome);&#xD;
&#xD;
          -  documented hypersensitivity to one of the components,&#xD;
&#xD;
          -  local infection of the injection sites;&#xD;
&#xD;
          -  intake of anticoagulants or muscle relaxing medications;&#xD;
&#xD;
          -  recreational drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominik A Ettlin, MD, DMD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominik A Ettlin, MD, DMD</last_name>
    <phone>+41 44 6343254</phone>
    <email>dominik.ettlin@zzm.uzh.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Zurich, Center of Dental Medicine</name>
      <address>
        <city>Zurich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.cephalon.eu/products/sensory/algomed/</url>
    <description>Homepage Company used Medical Device Algomed</description>
  </link>
  <reference>
    <citation>Ettlin DA, Sommer I, Brönnimann B, Maffioletti S, Scheidt J, Hou MY, Lukic N, Steiger B. Design, construction, and technical implementation of a web-based interdisciplinary symptom evaluation (WISE) - a heuristic proposal for orofacial pain and temporomandibular disorders. J Headache Pain. 2016 Dec;17(1):77. doi: 10.1186/s10194-016-0670-5. Epub 2016 Aug 31.</citation>
    <PMID>27581159</PMID>
  </reference>
  <reference>
    <citation>Iwasaki LR, Gonzalez YM, Liu H, Marx DB, Gallo LM, Nickel JC. A pilot study of ambulatory masticatory muscle activities in temporomandibular joint disorders diagnostic groups. Orthod Craniofac Res. 2015 Apr;18 Suppl 1:146-55. doi: 10.1111/ocr.12085.</citation>
    <PMID>25865543</PMID>
  </reference>
  <reference>
    <citation>Silva LC, Nogueira TE, Rios LF, Schimmel M, Leles CR. Reliability of a two-colour chewing gum test to assess masticatory performance in complete denture wearers. J Oral Rehabil. 2018 Apr;45(4):301-307. doi: 10.1111/joor.12609. Epub 2018 Feb 9.</citation>
    <PMID>29356092</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2021</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Zurich</investigator_affiliation>
    <investigator_full_name>Dominik Ettlin</investigator_full_name>
    <investigator_title>Study Principal Investigator, MD, DMD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bruxism</mesh_term>
    <mesh_term>Sleep Bruxism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>incobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

